Atomo Diagnostics Management
Management criteria checks 4/4
Atomo Diagnostics' CEO is John Kelly, appointed in Jan 2010, has a tenure of 14.92 years. total yearly compensation is A$476.48K, comprised of 85.2% salary and 14.8% bonuses, including company stock and options. directly owns 1.15% of the company’s shares, worth A$140.03K. The average tenure of the management team and the board of directors is 2.7 years and 4.8 years respectively.
Key information
John Kelly
Chief executive officer
AU$476.5k
Total compensation
| CEO salary percentage | 85.2% |
| CEO tenure | 14.9yrs |
| CEO ownership | 1.2% |
| Management average tenure | 2.7yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth
Jul 05
We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth
Oct 10Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?
Jun 10We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn
Dec 06Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 01We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow
Jul 19Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)
Feb 26Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business
Jan 22Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like
Dec 18
When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?
Jul 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$476k | AU$406k | -AU$7m |
| Mar 31 2024 | n/a | n/a | -AU$7m |
| Dec 31 2023 | n/a | n/a | -AU$7m |
| Sep 30 2023 | n/a | n/a | -AU$9m |
| Jun 30 2023 | AU$542k | AU$417k | -AU$10m |
| Mar 31 2023 | n/a | n/a | -AU$9m |
| Dec 31 2022 | n/a | n/a | -AU$9m |
| Sep 30 2022 | n/a | n/a | -AU$7m |
| Jun 30 2022 | AU$533k | AU$368k | -AU$6m |
| Mar 31 2022 | n/a | n/a | -AU$6m |
| Dec 31 2021 | n/a | n/a | -AU$6m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$467k | AU$372k | -AU$6m |
| Mar 31 2021 | n/a | n/a | -AU$8m |
| Dec 31 2020 | n/a | n/a | -AU$10m |
| Sep 30 2020 | n/a | n/a | -AU$9m |
| Jun 30 2020 | AU$611k | AU$298k | -AU$9m |
| Mar 31 2020 | n/a | n/a | -AU$7m |
| Dec 31 2019 | n/a | n/a | -AU$5m |
| Sep 30 2019 | n/a | n/a | -AU$5m |
| Jun 30 2019 | AU$319k | AU$248k | -AU$5m |
Compensation vs Market: John's total compensation ($USD296.69K) is about average for companies of similar size in the Australian market ($USD290.31K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Kelly
14.9yrs
Tenure
AU$476,477
Compensation
Mr. John Michael Kelly founded Atomo Diagnostics Ltd. in 2010 and serves as its Chief Executive Officer & Managing Director. Mr. Kelly has significant med-tech experience, having held senior operational an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 14.9yrs | AU$476.48k | 1.15% A$ 140.0k | |
| Chief Operating Officer | 2.7yrs | AU$303.92k | 0.027% A$ 3.2k | |
| Finance Manager | no data | no data | no data | |
| Company Secretary | less than a year | no data | no data |
2.7yrs
Average Tenure
Experienced Management: AT1's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 14.7yrs | AU$476.48k | 1.15% A$ 140.0k | |
| Independent Non-Executive Director | 3.3yrs | AU$90.00k | no data | |
| Independent Non-Executive Director | 2.1yrs | AU$50.00k | no data | |
| Independent Non-Executive Director | 4.8yrs | AU$70.00k | 0.016% A$ 1.9k | |
| Independent Non-Executive Chairman | 13yrs | AU$130.00k | 0.51% A$ 62.0k | |
| Member of Advisory Board | no data | no data | no data |
4.8yrs
Average Tenure
Experienced Board: AT1's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:14 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atomo Diagnostics Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Martyn Jacobs | Canaccord Genuity |